Intellia Therapeutics (NASDAQ:NTLA)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Leerink Swann in a research report issued on Wednesday, March 14th. Leerink Swann also issued estimates for Intellia Therapeutics’ Q4 2018 earnings at ($0.46) EPS.
A number of other analysts also recently weighed in on NTLA. Oppenheimer restated a “hold” rating on shares of Intellia Therapeutics in a report on Tuesday, December 12th. ValuEngine downgraded shares of Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, November 15th. BidaskClub upgraded shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, December 29th. JMP Securities assumed coverage on shares of Intellia Therapeutics in a report on Thursday, March 8th. They issued an “outperform” rating on the stock. Finally, TheStreet downgraded shares of Intellia Therapeutics from a “c-” rating to a “d” rating in a report on Thursday, December 14th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the stock. Intellia Therapeutics has an average rating of “Buy” and a consensus target price of $34.83.
NTLA stock traded down $1.41 during mid-day trading on Wednesday, hitting $20.45. The company had a trading volume of 1,121,251 shares, compared to its average volume of 1,603,846. The stock has a market cap of $926.59, a P/E ratio of -10.88 and a beta of 2.83. Intellia Therapeutics has a 12-month low of $11.15 and a 12-month high of $35.99.
Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Wednesday, March 14th. The company reported ($0.61) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.16). The company had revenue of $6.70 million during the quarter, compared to analysts’ expectations of $8.84 million. Intellia Therapeutics had a negative return on equity of 31.27% and a negative net margin of 258.62%. The firm’s revenue for the quarter was up 19.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.31) EPS. research analysts forecast that Intellia Therapeutics will post -2.27 EPS for the current fiscal year.
In related news, Director Jean Francois Formela sold 39,245 shares of the company’s stock in a transaction dated Tuesday, March 20th. The shares were sold at an average price of $23.87, for a total transaction of $936,778.15. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Caribou Biosciences, Inc. sold 550,645 shares of the company’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $26.78, for a total transaction of $14,746,273.10. The disclosure for this sale can be found here. Corporate insiders own 12.80% of the company’s stock.
A number of large investors have recently modified their holdings of the stock. Slow Capital Inc. bought a new position in Intellia Therapeutics during the 4th quarter valued at about $294,000. MetLife Investment Advisors LLC bought a new position in Intellia Therapeutics in the 4th quarter worth about $146,000. Millennium Management LLC bought a new position in Intellia Therapeutics in the 4th quarter worth about $683,000. TIAA CREF Investment Management LLC grew its stake in Intellia Therapeutics by 5.4% in the 4th quarter. TIAA CREF Investment Management LLC now owns 40,415 shares of the company’s stock worth $777,000 after acquiring an additional 2,076 shares in the last quarter. Finally, Teachers Advisors LLC grew its stake in Intellia Therapeutics by 22.4% in the 4th quarter. Teachers Advisors LLC now owns 31,950 shares of the company’s stock worth $614,000 after acquiring an additional 5,856 shares in the last quarter. Institutional investors own 57.10% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Leerink Swann Reaffirms “Outperform” Rating for Intellia Therapeutics (NASDAQ:NTLA)” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/07/intellia-therapeutics-ntla-outperform-rating-reaffirmed-at-leerink-swann.html.
About Intellia Therapeutics
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.